


## Data Sheet

### Product Information

Catalog Number	BP13933
Product Name	ICG001
Description	ICG-001 antagonizes Wnt/ $\beta$ -catenin/TCF-mediated transcription and specifically binds to element-binding protein (CREB)-binding protein (CBP) with IC <sub>50</sub> of 3 $\mu$ M, but is not the related transcriptional coactivator p300.
Targets&IC <sub>50</sub>	CBP:3 $\mu$ M
In vitro	PRI-724 binds specifically to CBP but not the related transcriptional coactivator p300, thereby disrupting the interaction of CBP with $\beta$ -catenin. Treatment with PRI-724 selectively induces apoptosis in colon carcinoma cells but not in normal colonic epithelial cells and reduces in vitro growth of colon carcinoma cells.
In vivo	PRI-724 exhibits antitumor activity in the mouse xenograft models of colon cancer. The initial results of the Phase I clinic trial of PRI-724 has been disclosed publically. The drug exhibits an acceptable toxicity profile with only one dose-limiting toxicity of grade 3 reversible hyperbilirubinaemia. An Open-Label dose-escalation phase I/II study of PRI-724 for patients with advanced myeloid malignancies is still ongoing.
Synonyms	PRI-724 isomer, PRI-724
CAS No.	847591-62-2
Chemical Formula	C <sub>33</sub> H <sub>32</sub> N <sub>4</sub> O <sub>4</sub>
Molecular Weight	548.63

Solubility	Ethanol: 27.4 mg/mL (50 mM) DMSO: 54.9 mg/mL (100 mM)
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year
Chemical Structure OR Tested Image	

Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

<https://www.purduebio.com>

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022